Songjiang Ma Sells 2,000 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) President Songjiang Ma sold 2,000 shares of the company's stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $10.97, for a total transaction of $21,940.00. Following the completion of the sale, the president now owns 2,808,824 shares of the company's stock, valued at approximately $30,812,799.28. This trade represents a 0.07% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Songjiang Ma also recently made the following trade(s):

• On Friday, May 23rd, Songjiang Ma sold 182 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.24, for a total transaction of $1,863.68.
• On Wednesday, March 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.13, for a total transaction of $20,260.00.
• On Monday, March 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.09, for a total transaction of $24,180.00.
• On Friday, March 14th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.31, for a total transaction of $24,620.00.
• On Wednesday, March 12th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.74, for a total transaction of $23,480.00.
• On Monday, March 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.14, for a total transaction of $20,280.00.
• On Friday, March 7th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.25, for a total transaction of $20,500.00.

Gyre Therapeutics Price Performance

GYRE traded down $0.36 during trading on Friday, reaching $9.10. The company had a trading volume of 231,034 shares, compared to its average volume of 114,861. The business's fifty day moving average price is $8.96 and its 200 day moving average price is $10.49. The company has a market cap of $853.20 million, a P/E ratio of 455.00 and a beta of 1.90. Gyre Therapeutics, Inc. has a 12 month low of $6.11 and a 12 month high of $19.00.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last posted its quarterly earnings results on Friday, May 9th. The company reported $0.03 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.03. The firm had revenue of $22.06 million for the quarter, compared to analyst estimates of $28.40 million. Gyre Therapeutics had a negative net margin of 84.57% and a negative return on equity of 118.43%.

Analysts Set New Price Targets

Separately, Noble Financial initiated coverage on shares of Gyre Therapeutics in a report on Tuesday, March 11th. They set an "outperform" rating for the company.

Hedge Funds Weigh In On Gyre Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. SBI Securities Co. Ltd. acquired a new stake in shares of Gyre Therapeutics in the 4th quarter valued at approximately $1,225,000. Barclays PLC raised its holdings in Gyre Therapeutics by 13.5% during the 4th quarter. Barclays PLC now owns 10,543 shares of the company's stock worth $128,000 after purchasing an additional 1,255 shares during the last quarter. Wells Fargo & Company MN raised its holdings in Gyre Therapeutics by 29.4% during the 4th quarter. Wells Fargo & Company MN now owns 4,016 shares of the company's stock worth $49,000 after purchasing an additional 913 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in Gyre Therapeutics by 11.1% during the 4th quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company's stock worth $168,000 after purchasing an additional 1,389 shares during the last quarter. Finally, Northern Trust Corp grew its position in shares of Gyre Therapeutics by 9.1% during the 4th quarter. Northern Trust Corp now owns 103,382 shares of the company's stock worth $1,251,000 after buying an additional 8,624 shares during the period. 23.99% of the stock is currently owned by institutional investors and hedge funds.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.